Attenuation of withdrawal signs, blood cortisol, and glucose level with various dosage regimens of morphine after precipitated withdrawal syndrome in mice by Motaghinejad, M. et al.
Iran J Med Sci January 2016; Vol 41 No 1 53
IJMS
Vol 41, No 1, January 2016
Attenuation of Withdrawal Signs, Blood 
Cortisol, and Glucose Level with Various 
Dosage Regimens of Morphine after 
Precipitated Withdrawal Syndrome in Mice
Majid Motaghinejad1, PhD;  
Goudarz Sadeghi-Hashjin2, PhD;  
Mohammad Kazem Koohi2, PhD;  
Seyed Morteza Karimian3, PhD
1Department of Pharmacology, School 
of Medicine, Iran University of Medical 
Sciences, Tehran, Iran;  
2Department of Pharmacology and 
Toxicology, Faculty of Veterinary 
Medicine, University of Tehran, Tehran, 
Iran; 
3Department of Physiology, School of 
Medicine, Tehran University of Medical 
Sciences, Tehran, Iran
Correspondence:  
Majid Motaghinejad, PhD;  
Department of Pharmacology, 
School of Medicine, Iran University of 
Medical Sciences, Hemmat Highway, 
Beside the Milad Tower,  
P.O. Box: 1449614525, Tehran, Iran  
Tel/Fax: +98 939 1974237 
Email: m-motaghinejad@razi.tums.ac.ir
Received: 13 April 2014
Revised: 7 June 2014
Accepted: 29 June 2014
Abstract
Morphine withdrawal usually results in unsuccessful outcomes. 
Despite partial benefits from alternative substances such as 
methadone, its use may not lead to the desired result due to the 
lack of mental tranquility during the withdrawal period. In this 
study, by means of an animal model, morphine itself was used 
to manage morphine dependence. Forty mice were divided into 
5 groups, in which 4 groups became dependent by increasing 
daily doses of morphine for 7 days (15-45 mg/kg). Afterwards, 
the animals received morphine for 14 days by either of the 
following regimens:
• Once daily 45 mg/kg (positive controls)
•  Increasing the interval (each time 6 hours longer than the 
previous interval)
•  Irregular interval in every 36, 12 and 24 hours until the 
21th day
•  12, 24, 36 hours decreasing doses (each time 2.5 mg/kg less 
than the former dosage).
Negative controls received saline solution only. On day 22, 
total withdrawal index (TWI) was determined by injecting 
3 mg/kg of naloxone. Thereafter, blood samples were taken for 
the measurement of cortisol and glucose levels. TWI significantly 
decreased in all test groups in comparison with the positive control 
animals (P<0.001). Cortisol levels significantly decreased when 
either the dosage or the administration frequencies were decreased 
on a regular and gradual basis (P<0.005). Blood glucose levels 
significantly decreased in animals that received decreasing doses 
of morphine (P<0.005). This study suggests that no other measures 
may be required in clinical practice except for changing the dosage 
regimen of morphine for the cessation of self-administration.
Please cite this article as: Motaghinejad M, Sadeghi-Hashjin G, Koohi MK, 
Karimian SM. Attenuation of Withdrawal Signs, Blood Cortisol, and Glucose 
Level with Various Dosage Regimens of Morphine after Precipitated Withdrawal 
Syndrome in Mice. Iran J Med Sci. 2016;41(1):53-58.
Keywords ● Morphine ● Cortisol ● Glucose ● Substance-Related 
Disorders ● Withdrawal syndrome
What’s Known
•	 Many	 previous	 basic	 and	 clinical	
data and treatment approaches were 
done on the application of a secondary 
drug to manage opioid dependency. 
However, these drugs have side effects 
and are often not associated with a 
favorable outcome.
•	 There	 was	 a	 need	 to	 introduce	
a new approach for opioid withdrawal 
syndrome management.
What’s New
•	 This	study	considered	the	influence	
of altered morphine dosage regimens 
on	 detoxification	 and	 attenuation	 of	 its	
withdrawal signs. 
•	 Morphine	 itself	 was	 used	 against	
morphine-induced dependency and 
altered morphine dosage regimen was 
used for opioid withdrawal syndrome 
management.
Introduction
The usage of opioids has long been accepted as a standard pain 
relief method in patients with cancer and acute pain.1 One of the 
major problems with long-term use of opioids such as morphine 
is drug dependency. It is characterized by physical dependence 
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and withdrawal syndrome resulting in sudden 
discontinued usage of opioid agonist or usage 
of opioid antagonist such as naloxone.2,3 Clinical 
approach to manage the withdrawal syndrome is 
mostly based on pattern detoxification of the opioid 
substance using medication or a weak, long-
acting opioid agent instead of the main drug.4-6 
Despite the immense benefits of drugs used to 
treat dependency and due to inadequate sedation 
of these drugs, the use of mentioned agent is 
often not associated with a favorable outcome.7-9
Morphine withdrawal is characterized by 
an increase in the hypothalamus-pituitary–
adrenocortical (HPA) axis activity that causes 
an increase in corticosterone and blood cortisol 
levels. These hormones are the main hormones 
involved in stress in rodent. They are responsible 
for stress and anxiety of withdrawal period and 
probably glucose levels.10 Chronic use of opioids 
causes key changes in pituitary–adrenal axis, 
which induces changes in physiological status of 
anxiety and stress situation.11 Based on previous 
studies, blood glucose levels changed in 
dependent mice. This study showed that stable 
and fixed dose of opioid can alter the blood 
glucose and other endocrine factors.12
The aim of the present study was to evaluate 
possible influence of altered morphine dosage 
regimens on detoxification and attenuation of 
its withdrawal signs. In addition to observe the 
signs of morphine abstinence, blood cortisol and 
glucose concentrations were also measured. 
These factors were measured as parameters 
involved in the stress situation and confirmation of 
our protocol’s effectiveness in the management 
of withdrawal syndrome.
Materials and Methods
Animals
Forty male adult Balb/c mice were obtained 
from Pasteur institute of Iran (Tehran, Iran). 
The average weight and age were 27.5 g 
and 8 weeks, respectively. The mice were 
held at room temperature with free access to 
commercial chow and tap water. Light and dark 
periods were supplied with 12 h cycles and 
controlled temperature (22±2ºC). The protocol 
was approved as an undergraduate research 
project by the Research Council of the University 
of Tehran, Faculty of Veterinary Medicine. The 
animals were kept and treated according to the 
university animal care guideline.
Induction of Morphine Dependency (Days 1-7)
Animals were divided randomly into 5 groups 
of 8, and were treated once a day at 8 a.m. 
subcutaneously with either saline solution 
(SHAM) or morphine sulphate (morphine 15, 20, 
25, 30 35, 40, and 45 mg/kg in 7 coming days, 
respectively).
Maintenance of Morphine Administration 
(Days 8-21)
On the 8th day, group 1 (SALINE-NEG 
CONTROL) received saline and the remaining 
four groups were treated in four different ways. On 
the last day, group 2 received morphine at doses of 
45 mg/kg, at fixed intervals of 24 h up to the 21th day 
(MOR45-POS CONTROL). Group 3 (MOR45-
INC INTERVAL) received morphine (45 mg/kg) at 
increasing intervals of 6 hours (i.e. 30 h, 36 h, 42 h, 
48 h, 54 h, 60 h, and 66 h) in the coming days. 
Group 4 (MOR45-IRREG INTERVAL) received 
morphine (45 mg/kg) at irregular intervals of 36 h, 
12 h, 36 h, 12 h, 36 h, 12 h, 24 h, 36 h, 12 h, 36 h, 
12 h, 36 h, 12 h, and 24 h. The last group (MOR-
DEC DOSE) received morphine at 24 h intervals 
in decreasing dosage manner of 42.5, 40, 37.5, 
35, 32.5, 30, 27.5, 25, 22.5, 20, 17.5, 15, 12.5, 
and 10 mg/kg, respectively.
Evaluation of Withdrawal Syndrome (Day 22)
On the 21st day, all animals received 3 mg/kg of 
naloxone sulfate at 8 a.m. Then, they were placed 
in chambers having 15×20×50 cm (w×d×h) 
dimensions, and were monitored for 30 minutes 
to record the signs of withdrawal syndrome. 
14-scale behavior was recorded and the rate of 
each behavior was divided by a weighing factor 
(Table1) and the results were added to derive the 
total withdrawal index (TWI) for each animal.
Measuring Blood Cortisol and Glucose
After behavioral studies, the whole blood 
was collected and the levels of serum cortisol 
and glucose were measured based on μg/dl and 
mg/dl, respectively.
Measuring Weight Changes in Animals
On the first day before the injection of 
morphine and on the 22nd day before the 
injection of naloxone, all animals were weighed. 
Table 1: Weighing factors (WFs) of different withdrawal 
signs of morphine in the mouse
Behavior WF Behavior WF
Jumping 4 Body grooming 10
Head shake 5 Face wipes 10
Wet dog shake 5 Swallowing 10
Paw tremor 5 Teeth chattering 10
Writhing 5 Dysphoria 10
Walking sniffing 5 Rearing 20
Sniffing 5 Chewing 20
Penile licking 5 - -
  Morphine Dosage Regimens and Withdrawal Signs
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The weight change of animals was calculated as 
a percentage by the following formula.
Difference of the mice weight as percent =
Mice weight at the first of period-Mice weight at the 
last of period
Mice weight at the first of period
Drugs and Chemicals
Morphine sulphate was a product of 
Temad Company (Tehran, Iran). Naloxone 
was purchased from Tolid-e Darou Company 
(Tehran, Iran).
Statistical Analysis
Data were averaged in every experimental 
group and expressed as mean±standard 
error of the mean (SEM). Then, differences 
between the control and morphine-dependent 
groups were evaluated by unpaired Student’s 
t-test. Differences among groups receiving 
various dosage regimens of morphine were 
first compared by one-way ANOVA and then 
group-by-group with Bonferroni post hoc t-test. 
P values <0.05 and <0.001 were considered 
statistically significant.
Results
Total Withdrawal Index (TWI)
TWI increased by 67% from 17.8±0.5 
in the controls (SALINE-NEG CONTROL 
group) to 54.8±1.1 in the morphine dependent 
(MOR45-POS CONTROL) animals (P<0.001). 
In comparison with MOR45-POS CONTROL 
animals, TWI was decreased by 44%, 33%, and 
41% in MOR45-INC INTERVAL, MOR45-IRREG 
INTERVAL, and MOR-DEC DOSE groups, 
respectively. The difference reached the level 
of significance in MOR45-INC INTERVAL and 
MOR-DEC DOSE groups (P<0.05) (Figure 1).
Blood Cortisol Levels (BCL)
BCL increased by 57% from 5.4±0.9 mg/dL in 
SALINE-NEG CONTROL group to 12.7±1 mg/dL 
in MOR45-POS CONTROL animals (P<0.001). 
In comparison with MOR45-POS CONTROL 
animals, BCL was decreased by 37%, 11%, 
and 41% in MOR45-INC INTERVAL, MOR45-
IRREG INTERVAL, and MOR-DEC DOSE 
groups, respectively. The difference reached 
the level of significance in MOR45-INC 
INTERVAL and MOR-DEC DOSE groups 
(P<0.05) (Figure 2).
Blood Glucose Levels (BGL)
BGL increased by 30% from 
84.6±2.6 mg/dL in the SALINE-NEG CONTROL 
group to 121.5±2.6 mg/dL in the MOR45-POS 
CONTROL animals (P<0.001). In comparison 
with MOR45-POS CONTROL animals, BGL was 
decreased by 12%, 1%, and 28% in MOR45-
INC INTERVAL, MOR45-IRREG INTERVAL, 
and MOR-DEC DOSE groups, respectively. 
The difference reached the level of significance 
only in the MOR-DEC DOSE group (P<0.05) 
(Figure 3).
Body Weight Alteration (BWA)
SALINE-NEG CONTROL animals gained 
an increased body weight of 16.6±3.8% 
within 21 days of the treatment, whereas the 
MOR45-POS CONTROL animals lost 2±1.5% 
of their weights (P<0.001). The weight loss 
was prevented in the MOR45-INC INTERVAL, 
MOR45-IRREG INTERVAL and MOR-DEC 
DOSE animals in comparison with the MOR45-
POS CONTROL group, which reached the 
level of significance in MOR-DEC DOSE group 
(P<0.05) (Figure 4).
Figure 1: Shows total withdrawal index (TWI) after naloxone 
injection in the SALINE-NEG CONTROL, MOR45-POS 
CONTROL, MOR45-INC INTERVAL, MOR45-IRREG 
INTERVAL, and MOR-DEC DOSE groups
N= 8 per group
***P<0.001 compared with SALINE-NEG CONTROL group
#P<0.05 compared with MOR45-POS CONTROL group
Figure 2: Shows blood cortisol levels after naloxone injection 
in the SALINE-NEG CONTROL, MOR45-POS CONTROL, 
MOR45-INC INTERVAL, MOR45-IRREG INTERVAL, and 
MOR-DEC DOSE groups
N= 8 per group
***P<0.001 compared with SALINE-NEG CONTROL group
#P<0.05 compared with MOR45-POS CONTROL group
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Discussion
In the present study, a new fascinating area 
of work for narcotic withdrawal strategies is 
put forward. It is possible to use the drug of 
abuse to eliminate the same drug instead of 
using other replacing substances. Indeed, 
changes in the pattern of opioid administration, 
including decreased frequency of application, 
gradual decrease in drug dosage, and irregular 
administration intervals may lead to the decreased 
intensity of morphine withdrawal syndrome. 
Interestingly, strategies used in this experimental 
work, especially a gradual decrease in morphine 
dosage, did not affect the general health of the 
animals as depicted from the data related to 
weight gain or loss during the experiments.
Several studies have been performed in 
the field of morphine withdrawal syndrome, 
in which various opioids such as naltrexone, 
dextromethorphan, methadone, tramadol, 
and buprenorphine were used as morphine 
replacement. Besides, non-opioid drugs 
have been applied to decrease the signs of 
morphine withdrawal by manipulating specific 
neurotransmitter re-uptake or affecting cerebral 
amino acids with the advantages like longer 
duration of action and lesser side effects in 
comparison with opioid agents.5,6,9,13-15
The present study shows that increasing 
the intervals of morphine injections without 
changing the dosages and irregular instead 
of regular injection reduces the symptoms of 
withdrawal syndrome significantly. We can 
justify that through increasing the intervals by 
adding 6 hours to dosage intervals in each time 
of injection, the central nervous system (CNS) 
does not encounter regular morphine intake 
and its award activating system abolishes and 
can provide a condition to reduce morphine 
dependence.14 Due to the regular and 
continual reduction of morphine doses in the 
consequential injections (each time 2.5 mg/kg 
less than the previous time), it is prevented 
from encountering the opioid receptors with 
morphine. In fact, sudden termination of the 
drug dosage is replaced by regular decrease of 
the drug dosage. This method is similar to the 
mechanism of the effect of long-term agonist 
medications such as methadone, tramadol 
and buprenorphine and antagonist such as 
nalteroxone.14
The morphine withdrawal syndrome is 
revealed by an increase in the hypothalamus–
pituitary–adrenocortical (HPA) axis activity. 
The origin of this activity is in cellular events, 
because morphine dependence increase HPA 
axis activity with changes in gene expression 
in selective neurons of the paraventricular 
nucleus.13 Our study showed that morphine 
doses in the dependent positive control group 
caused a significant increase in the blood 
cortisol in comparison with the independent 
negative control group during the withdrawal 
syndrome period. This result is arguable with 
the increasing level of stress in mice and 
consequently with increasing the cortisol 
secretion in the withdrawal period and 
dependency level in mice.16
On the other hand, by applying the treatment 
protocols, decreased dosage as well as 
increased intervals did not increase the blood 
concentrations of cortisol, indicating the lack of 
a stressful condition for the animals. Actually, 
increasing intervals of dosage and regular 
decreasing of morphine dosage in the third 
treatment group caused a significant reduction 
in the blood cortisol level in comparison 
with the dependent positive control group. 
We established that by using the treatment 
protocols, the level of stress decreased in 
the animal during the withdrawal syndrome 
period and consequently cortisol level was 
attenuated.17,18
Figure 3: Shows blood glucose levels after naloxone 
injection in the SALINE-NEG CONTROL, MOR45-POS 
CONTROL, MOR45-INC INTERVAL, MOR45-IRREG 
INTERVAL, and MOR-DEC DOSE groups
N= 8 per group
***P<0.001 compared with the C group
#P<0.05 compared with MOR45-POS CONTROL group
Figure 4: Shows body weight alterations in the mouse 
within 21 days in SALINE-NEG CONTROL, MOR45-POS 
CONTROL, MOR45-INC INTERVAL, MOR45-IRREG 
INTERVAL, and MOR-DEC DOSE groups
N=8 per group
***P<0.001 compared with SALINE-NEG CONTROL group
#P<0.05 compared with MOR45-POS CONTROL group
  Morphine Dosage Regimens and Withdrawal Signs
Iran J Med Sci January 2016; Vol 41 No 1 57
Park and colleagues had shown that the 
level of glucose is elevated in morphine-
dependent mice.19 As a result of stress and 
glucocorticoid secretion, we expected a rise 
in blood glucose levels during the withdrawal 
period. Indeed, this happened in the positive 
controls. Neither the increased intervals nor 
irregular morphine application prevented the 
glucose increase. However, gradual decrease 
of the morphine dosage significantly prevented 
glucose increase in the blood. One of the 
possible mechanisms for the hyperglycemic 
response after morphine withdrawal syndrome 
is that stress-induced hypercortisolism 
may have an opioid effect on the pancreas, 
stimulating glucagon secretion and thereby 
causing hepatic glucose output.20
Finally, the results of weight changes (by 
percent) in the control and under treatment 
groups showed that during opioids consumption 
in the positive control group, animals 
encountered a negative balance and even lost 
weight during the treatment period. However, in 
the negative control group they had a significant 
weight increase in comparison with the positive 
control group. Applying experimental protocols 
to the test group by regular decreasing intervals 
of morphine dosages caused an increase in the 
weight of dependent animals. The increasing 
intervals of morphine dosages or irregular 
morphine injection instead of regular injection 
did not lead to any meaningful weight change 
in comparison with the positive control animals. 
We can argue this results with a basic concept 
that addiction to opioids cause a decrease of 
appetite, increase saturation hormone, suppress 
the appetite center in the brain, and also reduced 
metabolic activity of nutrition in the body, thus 
it has a negative effect on the body weight 
gain.19,20 However, increasing the intervals 
of morphine dosages or irregular morphine 
injection instead of the regular injection as well 
as regular decrease of morphine dosages, 
causes attenuation of this morphing effect on the 
metabolism and appetite and thus suppresses 
morphine induced anorexia.
Conclusion
This study showed that changing the dosage 
regimen of morphine administration could 
be useful for the management of withdrawal 
syndrome and cortisol (as the main marker of 
anxiety) of the cessation period. This method 
is recommended as an adjunct treatment 
of methadone or other standard therapy of 
dependency. However, in human clinical practice, 
we would be exposed to more challenges and 
there is a need for further precise evaluation of 
our protocol.
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